ANIMAL-MODELS FOR ANTI-AIDS THERAPY

被引:12
作者
KOCH, JA
RUPRECHT, RM
机构
[1] HARVARD UNIV, SCH MED,DANA FARBER CANC INST, VIRAL PATHOGENESIS LAB,44 BINNEY ST, BOSTON, MA 02115 USA
[2] HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA
[3] HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA
关键词
ANIMAL MODEL; ANTIVIRAL THERAPY; ANTI-AIDS THERAPY; DRUG DEVELOPMENT; TRANSGENIC MOUSE; CHIMERIC MOUSE;
D O I
10.1016/0166-3542(92)90069-H
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Primate and non-primate species have been used to study the pathobiology of the simian immunodeficiency virus (SIV) and of the human immunodeficiency virus type 1 (HIV-1), respectively, and to develop new therapeutic regimes. Transgenic mice which express either the entire HIV-1 provirus or subgenomic fragments have been used to analyze viral gene products in vivo and may serve as models for the development of agents targeted to select viral functions. Chimeric mice which were created by transplanting human hematolymphoid cells into mice suffering from congenital severe combined immunodeficiency (scid/scid or so called SCID mice), can be infected with HIV-1 and allow one to study the entire HIV-1 replicative cycle. Type C murine leukemia virus models have been used to develop new prophylactic and therapeutic strategies but their use is restricted to the evaluation of select antiviral drug inhibition, targeted to retroviral genes common to both Lentivirinae and Oncovirinae. The role of various animal model systems in the development of anti-HIV-1 and anti-AIDS therapies is summarized.
引用
收藏
页码:81 / 109
页数:29
相关论文
共 151 条
[1]   IDENTIFICATION OF A CD4 HOMOLOG IN THE CAT [J].
ACKLEY, CD ;
HOOVER, EA ;
COOPER, MD .
TISSUE ANTIGENS, 1990, 35 (02) :92-98
[2]   IMMUNOLOGICAL ABNORMALITIES IN PATHOGEN-FREE CATS EXPERIMENTALLY INFECTED WITH FELINE IMMUNODEFICIENCY VIRUS [J].
ACKLEY, CD ;
YAMAMOTO, JK ;
LEVY, N ;
PEDERSEN, NC ;
COOPER, MD .
JOURNAL OF VIROLOGY, 1990, 64 (11) :5652-5655
[3]   PRODUCTION OF ACQUIRED IMMUNODEFICIENCY SYNDROME-ASSOCIATED RETROVIRUS IN HUMAN AND NONHUMAN CELLS TRANSFECTED WITH AN INFECTIOUS MOLECULAR CLONE [J].
ADACHI, A ;
GENDELMAN, HE ;
KOENIG, S ;
FOLKS, T ;
WILLEY, R ;
RABSON, A ;
MARTIN, MA .
JOURNAL OF VIROLOGY, 1986, 59 (02) :284-291
[4]   INFECTION OF MACACA-NEMESTRINA BY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
AGY, MB ;
FRUMKIN, LR ;
COREY, L ;
COOMBS, RW ;
WOLINSKY, SM ;
KOEHLER, J ;
MORTON, WR ;
KATZE, MG .
SCIENCE, 1992, 257 (5066) :103-106
[5]   SEVERE IMMUNODEFICIENCY DISEASE INDUCED BY A DEFECTIVE MURINE LEUKEMIA-VIRUS [J].
AZIZ, DC ;
HANNA, Z ;
JOLICOEUR, P .
NATURE, 1989, 338 (6215) :505-508
[6]   DETAILED MAPPING OF THE ANTIGENICITY OF THE SURFACE UNIT GLYCOPROTEIN OF EQUINE INFECTIOUS-ANEMIA VIRUS BY USING SYNTHETIC PEPTIDE STRATEGIES [J].
BALL, JM ;
RUSHLOW, KE ;
ISSEL, CJ ;
MONTELARO, RC .
JOURNAL OF VIROLOGY, 1992, 66 (02) :732-742
[7]   ANTIRETROVIRUS ACTIVITY OF 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE (PMEA) INVIVO INCREASES WHEN IT IS LESS FREQUENTLY ADMINISTERED [J].
BALZARINI, J ;
NAESENS, L ;
DECLERCQ, E .
INTERNATIONAL JOURNAL OF CANCER, 1990, 46 (02) :337-340
[8]   9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE (PMEA) EFFECTIVELY INHIBITS RETROVIRUS REPLICATION INVITRO AND SIMIAN IMMUNODEFICIENCY VIRUS-INFECTION IN RHESUS-MONKEYS [J].
BALZARINI, J ;
NAESENS, L ;
SLACHMUYLDERS, J ;
NIPHUIS, H ;
ROSENBERG, I ;
HOLY, A ;
SCHELLEKENS, H ;
DECLERCQ, E .
AIDS, 1991, 5 (01) :21-28
[9]  
BALZARINI J, 1990, J ACQ IMMUN DEF SYND, V3, P1140
[10]   ISOLATION OF A T-LYMPHOTROPIC RETROVIRUS FROM A PATIENT AT RISK FOR ACQUIRED IMMUNE-DEFICIENCY SYNDROME (AIDS) [J].
BARRESINOUSSI, F ;
CHERMANN, JC ;
REY, F ;
NUGEYRE, MT ;
CHAMARET, S ;
GRUEST, J ;
DAUGUET, C ;
AXLERBLIN, C ;
VEZINETBRUN, F ;
ROUZIOUX, C ;
ROZENBAUM, W ;
MONTAGNIER, L .
SCIENCE, 1983, 220 (4599) :868-871